Molecular Templates Inc

Molecular Templates — Investor Presentation (September 2019)

26 slides from Molecular Templates's investor presentation, Sep 24, 2019

  1. Slide 1: Corporate Presentation September 2019

    MOLECULAR TEMPLATES Corporate Presentation I September 2019 (NASDAQ: MTEM) Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Except for statements of historical fact, the statements in this presentation are forward-looking statements, including statements regarding the future development of our proprietary Engineered Toxin Body (ETB) technology; the future development of evofosfamide; our milest

  3. Slide 3: Engineered Toxin Bodies: Novel Approach With Broad Applicability

    Engineered Toxin Bodies Novel Approach With Broad Applicability

  4. Slide 4: Developing Novel Oncology Therapies With Engineered Toxin Bodies

    MTEM Developing Novel Oncology Therapies With Engineered Toxin Bodies (ETBs) Unique MOA Engineered Toxin Bodies (ETB) have the specificity of an antibody, can induce their own internalization, and act through a potent and unique mechanism of action: ribosomal destruction Advancing Pipeline MT-3724 h

  5. Slide 5: MT-3724 1st-Gen ETB Targeting CD20 for Lymphomas

    MT-3724 1st-Gen ETB Targeting CD20 for Lymphomas

  6. Slide 6: MT-3724: 1st-Gen ETB with Promising Signals of Activity in DLBCL

    Patients evaluable for efficacy in phase I (n=25) DLBCL or Mixed DLBCL/FL (n=19) Low serum RTX levels (n=13) 2 Complete Responses (CR) 1 Complete Metabolic Response (CMR) 2 Partial Responses (PR) 3 Stable Disease (SD) (49%, 47% tumor reduction) 5 Progressive Disease (PD) 38% Objective Response Rate

  7. Slide 7: Clinical Evidence of Single-Agent Activity with MT-3724

    Clinical Evidence of Single-Agent Activity with MT-3724 7/30/15 (Cycle 5) 4/14/15 (Cycle 2) 5/28/15 (Cycle 4) 2/27/15 (Baseline) 77 y/o transformed DLBCL, chemo-intolerant Treatment history BR + IFRT for follicular lymphoma: partial response obtained R-CHOP x 5; cycle 6 not given due to poor toleran

  8. Slide 8: Clinical Evidence of Single-Agent Activity with MT-3724

    Clinical Evidence of Single-Agent Activity with MT-3724 Mesenteric mass in left hemiabdomen (7.1 x 3.3 x 5.7 cm) 51 y/o with DLBCL treated at 20 mcg/kg of MT-3724 Treatment history: R-CHOP refractory, R-ICE refractory, PR on R-DAHP with auto-sct and relapse

  9. Slide 9: MT-3724 Compared With Polatuzumab and REGN1979 in DLBCL

    Polatuzumab (CD79b ADC) REGN1979 (CD20-CD3 Bispecific) MT-3724 (CD20 ETB) Patient demographics N=39 (DLBCL) Age = 67 Median # of prior therapies ≥ 3 N=39 (DLBCL) Age = 67 Median # of prior therapies = 3 N=12 (DLBCL w/ low/no RTX) Age = 67 Median # of prior therapies = 3 Efficacy ORR of 43.5% (17/39)

  10. Slide 10: MT-3724 DLBCL Development Progressing and Expanding

    MT-3724 DLBCL Development Progressing and Expanding Indication (Target) Preclinical Phase 1 Phase 2 Phase 3 Next Milestone MT-3724 Monotherapy R-R DLBCLa (2+ lines of therapy) Presentation of results at medical conference MT-3724 Monotherapy R-R DLBCL (2+ lines of therapy) Phase 2 study update in 2H

  11. Slide 11: 2nd-Gen Engineered Toxin Bodies

    2nd-Gen Engineered Toxin Bodies Increased Potency; Better Safety

  12. Slide 12: TAK-169 Targeting CD38 vs Monoclonal Antibodies

    CD38-targeting agents Monoclonal Antibody (Mab) (Darzalex®) Engineered Toxin Body (TAK-169) MOA Indirect CDC cell kill Direct cell kill (enzymatic ribosome inactivation) CD38 target interaction Binding Binding and internalization Limitations CD55/59 upregulation in failures, inhibiting immune respon

  13. Slide 13: Takeda Collaboration Economics

    Potential for $1.2 Billion+ and Meaningful Royalties to MTEM Multi-Target Collaboration Upfront fee + program plans for designated targets $5M Exercise of option to license ETBs $25M Total R&D and commercial milestones (across two targets) $547M Tiered royalties Mid single to low double-digits Taked

  14. Slide 14: MT-5111: 2nd-Gen ETB Targeting HER2

    HER2-targeting agents Mab: Herceptin, Perjeta ADC: Kadcyla TKI: Tykerb, Nerlynx Engineered Toxin Body (MT-5111) MOA Signal transduction blocker (Mabs, TKIs) Direct cell kill (ADC) Direct cell kill (enzymatic ribosome inactivation) HER2 target interaction Binding and internalization Binding and inter

  15. Slide 15: HER2 Modalities and Mechanisms of Resistance

    Monoclonal Antibody Tyrosine Kinase Inhibitor (TKI) Antibody Drug Conjugate (ADC) Engineered Toxin Body MOA Trastuzumab: Inhibits homodimerization, signaling Pertuzumab: Inhibits heterodimerization, signaling Lapatinib: kinase inhibitor Neratinib: kinase inhibitor Trastuzumab-DM1: Microtubule inhibi

  16. Slide 16: 3rd-Gen Engineered Toxin Bodies

    3rd-Gen Engineered Toxin Bodies Increased potency; better safety; antigen seeding

  17. Slide 17: 3rd-Gen Antigen Seeding: Altering the Tumor Immunophenotype

    3rd-Gen Antigen Seeding: Altering the Tumor Immunophenotype ETBs localize to ER/cytosol to “seed” tumors with foreign non-self antigens Antigen cleaved intracellularly and presented on cell surface in context with MHC-I Delivery of pp65 CMV antigen Mediate native CMV-specific T cell response to tumo

  18. Slide 18: 3rd-Gen ETB Targeting PD-L1: Rationale for Dual MOA

    3rd-Gen ETB targeting PD-L1: Rationale for Dual MOA Next-Gen SLTA Payload CMV pp65 antigen (or antigen of choice) Engineered Toxin Bodies Tumor cell Immune cell “Cold” tumor Not immunogenic “Hot” tumor Immune cells suppressed “Excluded” tumor Immune cells suppressed Checkpoint responsiveness MOA 1:

  19. Slide 19: Engineered Toxin Bodies: A Modular Scaffold

    Engineered Toxin Bodies A modular scaffold with unique advantages

  20. Slide 20: ETB Scaffold Has Modular Design for Maximal Drug Design Options

    ETB Scaffold Has Modular Design for Maximal Drug Design Options Monovalent Multi-valent scFv-ETB VHH-ETB TCR-ETB Bi-specific / bi-paratropic ETBs Modular Binding Formats Payload Formats Drug conjugates – site specific or multi-site conjugation Oligos, siRNAs – site specific or multi-site conjugation

  21. Slide 21: Engineered Toxin Bodies: Putting the Scaffold in Context

    Engineered Toxin Bodies Putting the scaffold in context

  22. Slide 22: ETB Scaffold Opportunity: Inherent Value of Scaffolds in Oncology

    CAR-T Bispecific ETB Efficacy ~35% CR in DLBCL w/ Flu ~30% ORR (10% CR) w/o Flu ~40% ORR (20% CR) in DLBCL (no conditioning) ~30-40% ORR in DLBCL Clinically validated advantages Novel MOA (T-cell engagement) Active against non-internalizing targets Novel MOA (T-cell engagement) Active against non-in

  23. Slide 23: Oncology Pipeline With Novel MOAs Driven by ETB Platform

    Program Partner Indication (Target) Preclinical Phase 1 Phase 2 Phase 3 MT-3724 DLBCLa monotherapy (CD20) DLBCL combinations (CD20) MT-5111 Multiple – solid tumors (HER2) TAK-169 Multiple Myeloma (CD38) MT-6035 (antigen seeding) Multiple – solid tumors (PD-L1) Takeda Target 1 Undisclosed Takeda Targ

  24. Slide 24: Multiple Important Milestones Expected in 2019

    Timing Milestone MT-3724 (CD20) 2H19 Update on Phase 2 GEMOX combination study 2H19 Update on Phase 2 Revlimid combination study in DLBCL 2H19 Update on Phase 2 monotherapy study MT-5111 (HER2) 2H19 Update on HER2 Phase 1 study TAK-169 (CD38) 2H19 Initiate Phase 1 study in multiple myeloma PD-L1 ETB

  25. Slide 25: Financial Highlights

    Top shareholders include: Market Capitalization ~$250M Market Capitalization , ~100,000 average daily trading volume Shares Outstanding ~36.9M shares outstanding (~44.0M fully diluted) as of 2Q19 10-Q filing Cash ~$72M in cash provides runway into 2021 Non-dilutive funding Non-dilutive funding from

  26. Slide 26: Molecular Templates www.mtem.com

    MOLECULAR TEMPLATES www.mtem.com (NASDAQ: MTEM)

Molecular Templates — Investor Presentation (September 2019) on 6ix